Business
DrazCanna, Inc. (OTCBB: SIBED) - A New, US Based, Public Cannabis Company paves its way into the Marijuana Bio-Pharmaceutical Research and Development Supply Chain
DrazCanna, Inc. (OTCBB: SIBED) - A New, US Based, Public Cannabis Company paves its way into the Marijuana Bio-Pharmaceutical Research and Development Supply Chain.
About this update from Drazcanna Inc
[{"type":"text","content":""Sometimes timing is everything for an entrepreneur". US Senate unanimously approves Marijuana Reform Bill on the same day that the House schedules cannabis legalization vote…and it's your first day as a U.S. public company in the cannabis industry; the realization of a 6+ year entrepreneurial journey.DEARBORN HEIGHTS, MI / ACCESSWIRE / March 28, 2022 / "The timing is unbelievable" exclaimed Hussein Anani, President of DrazCanna, Inc. For the leadership team at DrazCanna, the meetings with accountants and attorneys were continuing with next steps to finish the pending reverse merger laid out for the coming week.DrazCanna, Inc., (formerly known as Sibling Group Holdings, Inc.) originally filed with FINRA its related application for a name change and 1 for 24 reverse split on November 3rd, 2021 and was processed March 25th, 2021."To see our Senate unanimously pass legislation, this truly simplifies the challenges of navigating regulatory restrictions endured by early entrants into the medical cannabis market."The actions in both the Senate and House on Friday March 25th, 2022 in regards to providing much needed regulatory reform for Research and Development of Cannabis are the steps we believe are necessary to bring clarity to the conflict between USDA's designation of cannabis as a Schedule 1 narcotic with no medical use statement conflicted by the FDA and its approval of Epidiolex, an oral solution for the treatment of seizures associated with two rare and severe forms of childhood epilepsy in children as young as two years old containing parts extracted from the cannabis plant.With regulatory changes removing the obstacles with cannabis research and development, Hussein sees the "stigma" of cannabis finally being challenged which has hindered the country from truly embracing Bio-Pharmaceutical research and development of cannabis. "We all have personally seen family members, friends, or acquaintances that have had relationships, lives, and jobs damaged by the irresponsible use of drugs. However, we should not inhibit important research and development that represents an opportunity to develop potentially life-saving medicine which at a bare minimum improves the quality of life for children and adults," Hussein put forth passionately."We are excited as a team to move f...